Experience of using convalescent plasma for severe acute respiratory syndrome among healthcare workers in a Taiwan hospital

Kuo-Ming Yeh, Tzong-Shi Chiueh, L K Siu, Jung-Chung Lin, Paul K S Chan, Ming-Yieh Peng, Hsiang-Lin Wan, Jenn-Han Chen, Bor-Shen Hu, Cherng-Lih Perng, Jang-Jih Lu, Feng-Yee Chang, Kuo-Ming Yeh, Tzong-Shi Chiueh, L K Siu, Jung-Chung Lin, Paul K S Chan, Ming-Yieh Peng, Hsiang-Lin Wan, Jenn-Han Chen, Bor-Shen Hu, Cherng-Lih Perng, Jang-Jih Lu, Feng-Yee Chang

Abstract

Objectives: To describe the immunological responses and clinical outcome of coronavirus (SARS) infected healthcare workers (HCW) who had been administered with convalescent plasma as a treatment.

Methods: Convalescent plasma (500 mL) was obtained from each of three SARS patients and transfused into the three infected HCW. Donors were blood type O and seronegative for hepatitis B and C, HIV, syphilis and human T-cell lymphotropic virus types I and II (HTLV-I and -II). Serum antibody (IgG) titre was >640. Apharesis was performed with a CS 3000 plus cell separator followed by the forming of the convalescent phase plasma. As part of the routine check with donated plasma, the convalescent plasma was confirmed free of residual SARS-CoV by RT-PCR. Serial serum samples obtained from the recipients of the convalescent plasma were collected to undertake real-time quantitative RT-PCR for SARS-CoV for direct measurement of viral concentration. Specific immunoglobulin IgM and IgG concentrations were titrated using an antigen microarray developed in-house.

Results: Viral load dropped from 495 x 10(3), 76 x 10(3) or 650 x 10(3) copies/mL to zero or 1 copy/mL one day after transfusion. Anti-SARS-CoV IgM and IgG also increased in a time-dependent manner following transfusion. All three patients survived. One HCW became pregnant subsequently, delivering 13 months after discharge. Positive anti-SARS-CoV IgG was detected in the newborn. Passive transfer of anti-SARS-CoV antibody from the mother was considered as a possibility.

Conclusions: All infected HCW whose condition had progressed severely and who had failed to respond to the available treatment, survived after transfusion with convalescent plasma.

References

    1. Ho AS, Sung JJY, Chan-Yeung M. An outbreak of severe acute respiratory syndrome among hospital workers in a community hospital in Hong Kong. Ann Intern Med 2003; 139: 564–7.
    1. Lee N, Hui D, Wu A et al A major outbreak of severe acute respiratory syndrome in Hong Kong. N Engl J Med 2003; 348: 1986–94.
    1. Marra MA, Jones SJM, Astell CR et al The genome sequence of the SARS-associated coronavirus. Science 2003; 300: 1399–404.
    1. Peiris JSM, Lai ST, Poon LLM et al Coronavirus as a possible cause of severe acute respiratory syndrome. Lancet 2003; 361: 1319–25.
    1. So LK, Lau AC, Yam LY et al Development of a standard treatment protocol for severe acute respiratory syndrome. Lancet 2003; 361: 1615–7.
    1. Chu CM, Cheng VC, Hung IF et al Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings. Thorax 2004; 59: 252–6.
    1. Vastag B. Old drugs for a new bug: influenza, HIV drugs enlisted to fight SARS. JAMA 2003; 290: 1695–6.
    1. Wang Z, Ren L, Zhao X et al Inhibition of severe acute respiratory syndrome virus replication by small interfering RNAs in mammalian cells. J Virol 2004; 78: 7523–7.
    1. Cinatl J, Morgenstern B, Bauer G et al Treatment of SARS with human interferons. Lancet 2003; 362: 293–4.
    1. Wu CJ, Jan JT, Chen CM et al Inhibition of severe acute respiratory syndrome coronavirus replication by niclosamide. Antimicrob Agents Chemother 2004; 48: 2693–6.
    1. Wu CY, Jan JT, Ma SH et al Small molecules targeting severe acute respiratory syndrome human coronavirus. Proc Natl Acad Sci USA 2004; 101: 10012–7.
    1. Jahrling PB, Peters CJ. Passive antibody therapy of Lassa fever in Cynomolgus monkeys—importance of neutralizing antibody and Lassa virus-strain. Infect Immun 1984; 44: 528–33.
    1. Jahrling PB, Frame JD, Rhoderick JB et al Endemic Lassa fever in Liberia. IV. Selection of optimally effective plasma for treatment by passive immunization. Trans R Soc Trop Med Hyg 1985; 79: 380–4.
    1. Chan PK, Ip M, Ng KC et al Severe acute respiratory syndrome-associated coronavirus infection. Emerg Infect Dis 2003; 9: 1453–4.
    1. Ksiazek TG, Erdman D, Goldsmith CS et al A novel coronavirus associated with severe acute respiratory syndrome. N Engl J Med 2003; 348: 1953–66.
    1. Peiris JS, Chu CM, Cheng VC et al Clinical progression and viral load in a community outbreak of coronavirus-associated SARS pneumonia: a prospective study. Lancet 2003; 361: 1767–72.
    1. Soo YO, Cheng Y, Wong R et al Retrospective comparison of convalescent plasma with continuing high-dose methylprednisolone treatment in SARS patients. Clin Microbiol Infect 2004; 10: 676–8.
    1. Cheng Y, Wong R, Soo YO et al Use of convalescent plasma therapy in SARS patients in Hong Kong. Eur J Clin Microbiol Infect Dis 2005; 24: 44–6.

Source: PubMed

Sponsorer og samarbeidspartnere

Medisinsk tilstand

Legemiddelintervensjoner

3
Abonnere